Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

16.89
+1.8011.93%
Post-market: 16.85-0.0373-0.22%17:47 EDT
Volume:4.33M
Turnover:71.49M
Market Cap:832.81M
PE:-4.57
High:17.35
Open:15.25
Low:14.97
Close:15.09
52wk High:35.83
52wk Low:11.36
Shares:49.31M
Float Shares:32.11M
Volume Ratio:0.98
T/O Rate:13.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6975
EPS(LYR):-4.3239
ROE:-53.25%
ROA:-33.11%
PB:2.27
PE(LYR):-3.91

Loading ...

Arrivent Biopharma - Safety Profile in Furvent Consistent with Previous Studies, no New Safety Signals

THOMSON REUTERS
·
Oct 06

Arrivent Biopharma - Clinical Benefit Observed with Secondary Endpoints Including Pfs and Confirmed Orr

THOMSON REUTERS
·
Oct 06

Arrivent Announces Program Update from the Phase 3 Furvent Trial of Firmonertinib in First-Line Egfr Exon 20 Insertion Mutant Nsclc

THOMSON REUTERS
·
Oct 06

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Oct 06

ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Guggenheim

TIPRANKS
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Sep 15

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Sep 15

ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study

TIPRANKS
·
Sep 04

Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $47 from $44

THOMSON REUTERS
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

Simply Wall St.
·
Aug 16

ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target

TIPRANKS
·
Aug 13

ArriVent BioPharma Price Target Maintained with a $42.00/Share by BTIG

Dow Jones
·
Aug 13

ArriVent BioPharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ArriVent Biopharma Releases Corporate Presentation on Late-Stage Oncology Pipeline Led by Firmonertinib in EGFR-Mutant NSCLC

Reuters
·
Aug 13

ArriVent inks China partnership for ARR-002 development

TIPRANKS
·
Aug 13

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

Benzinga Earnings
·
Aug 13

Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jul 14

ArriVent BioPharma Stockholders Back Board and Auditor Slate

TIPRANKS
·
Jun 23